Source: Cardiovascular drugs and therapy. Unidade: FM
Subjects: HIPERCOLESTEROLEMIA, ERROS INATOS DO METABOLISMO, ENZIMAS PROTEOLÍTICAS, FATORES DE RISCO
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
GINSBERG, Henry N et al. Impact of age on the efficacy and safety of alirocumab in patients with heterozygous familial hypercholesterolemia. Cardiovascular drugs and therapy, v. 33, n. 1, p. 69-76, 2019Tradução . . Disponível em: https://doi.org/10.1007/s10557-019-06852-6. Acesso em: 11 nov. 2024.APA
Ginsberg, H. N., Tuomilehto, J., Hovingh, G. K., Cariou, B., Santos Filho, R. D. dos, Brown, A. S., et al. (2019). Impact of age on the efficacy and safety of alirocumab in patients with heterozygous familial hypercholesterolemia. Cardiovascular drugs and therapy, 33( 1), 69-76. doi:10.1007/s10557-019-06852-6NLM
Ginsberg HN, Tuomilehto J, Hovingh GK, Cariou B, Santos Filho RD dos, Brown AS, Sanganalmath SK, Koren A, Thompson D, Raal FJ. Impact of age on the efficacy and safety of alirocumab in patients with heterozygous familial hypercholesterolemia [Internet]. Cardiovascular drugs and therapy. 2019 ; 33( 1): 69-76.[citado 2024 nov. 11 ] Available from: https://doi.org/10.1007/s10557-019-06852-6Vancouver
Ginsberg HN, Tuomilehto J, Hovingh GK, Cariou B, Santos Filho RD dos, Brown AS, Sanganalmath SK, Koren A, Thompson D, Raal FJ. Impact of age on the efficacy and safety of alirocumab in patients with heterozygous familial hypercholesterolemia [Internet]. Cardiovascular drugs and therapy. 2019 ; 33( 1): 69-76.[citado 2024 nov. 11 ] Available from: https://doi.org/10.1007/s10557-019-06852-6
